
News|Articles|February 20, 2025
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
Author(s)Giuliana Grossi
While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Advertisement
Advertisement
Health care access and equity have recently faced mounting challenges across the US shaped by legislative policies, social determinants, and evolving treatment landscapes—a trend that appears set to accelerate in 2025. Abortion bans in the wake of the Dobbs v Jackson Supreme Court decision in 2022 and the preceding Texas Senate Bill 8 (SB8) in 2021 have introduced legal and ethical dilemmas, prompting a nationwide conversation including various perspectives among physicians, authors, and lawmakers.
Related to this article

A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.

Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.

Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.

Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.

Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.

Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.

The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Advertisement
Advertisement

